Yunlong Wang
Clinical trials sponsored by Yunlong Wang, explained in plain language.
-
New combo ablation aims to tame stubborn AFib
Disease control Not yet recruitingThis trial tests whether adding extra ablation lines to the standard pulsed-field ablation procedure helps people with long-standing atrial fibrillation (AF) stay in normal heart rhythm. 430 participants with AF lasting 1-3 years will be randomly assigned to receive either standa…
Phase: NA • Sponsor: Yunlong Wang • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Weight-Loss drug tirzepatide may help keep heart rhythm steady after ablation
Disease control Not yet recruitingThis trial tests whether adding tirzepatide (Mounjaro) to a structured lifestyle program reduces the return of atrial fibrillation within a year after catheter ablation in obese patients. About 710 participants with symptomatic AF and a BMI of 28 or higher (or 24 with other risk …
Phase: PHASE4 • Sponsor: Yunlong Wang • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Weight-Loss drug mounjaro could keep hearts in rhythm after ablation
Disease control Not yet recruitingThis study tests whether the diabetes and weight-loss drug tirzepatide (Mounjaro) can reduce the chance of atrial fibrillation coming back after a heart procedure called catheter ablation. About 602 adults with obesity and a type of heart failure (HFpEF) will get either tirzepati…
Phase: PHASE4 • Sponsor: Yunlong Wang • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC